Morie A Gertz

Nov 26, 2024 | cancernetwork.com | Morie A Gertz |Ajai Chari

November 26, 2024By Panelists discuss how the CEPHEUS trial’s demonstration of improved progression-free survival with daratumumab-VRd versus VRd alone in transplant not-preferred NDMM provides compelling evidence for quadruplet therapy in this setting, though considerations of cost, toxicity management, and patient selection remain important factors in implementation. Video content above is prompted by the following:What are your impressions of the CEPHEUS data that was recently presented?

Nov 19, 2024 | cancernetwork.com | Morie A Gertz |Ajai Chari

November 19, 2024By Panelists discuss how recent clinical trials have demonstrated improved outcomes with antibody-containing regimens and biomarker-driven approaches in patients with transplant not-preferred newly diagnosed multiple myeloma (NDMM). Video content above is prompted by the following:What are your perspectives on the data from the MAIA, BENEFIT, and IMROZ trials? How does the data impact frontline treatment for patients with NDMM who are not transplant-preferred?

Nov 12, 2024 | cancernetwork.com | Morie A Gertz |Ajai Chari

November 12, 2024By Panelists discuss how the decision between quadruplet versus triplet therapy depends on multiple factors, including cytogenetic risk status, insurance coverage/drug access, patient fitness to tolerate additional toxicity, and the strength of evidence supporting improved outcomes with 4-drug combinations.

Oct 29, 2024 | cancernetwork.com | Morie A Gertz |Ajai Chari

Panelists discuss how VRd (bortezomib, lenalidomide, dexamethasone) remains the standard frontline regimen for transplant-eligible newly diagnosed multiple myeloma (NDMM) patients, though some now consider adding daratumumab (dara-VRd) in high-risk cases. Video content above is prompted by the following:• What is your current approach to frontline therapy for transplant-preferred NDMM?

Sep 19, 2024 | onlinelibrary.wiley.com | Morie A Gertz

COMMENTARY The importance of autologous stem cell transplantation in improving outcomes in newly diagnosed patients with multiple myeloma Morie A. Gertz,  Corresponding Author Morie A. Gertz Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA Correspondence Morie A. Gertz, Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA. Email: [email protected] for more papers by this author Morie A. Gertz,  Corresponding Author Morie A.